Main Article Content



  1. Medical therapy selection in the outpatient eye clinic were determined.
  2. Treatment of prostaglandin analogue therapyfor primary open angle glaucoma was the most common glaucoma type.


Glaucoma is the second leading cause of blindness and the third cause of visual impairment. Glaucoma management includes medical therapy, laser, and incisions. This study aims to determine the selection of medical therapy in the outpatient eye clinic Soetomo General Academic Hospital Surabaya. This study was a retrospective descriptive study. The variables were type of glaucoma, visual acuity, intraocular pressure, and drug therapy. Data processing was done by collecting, grouping, and describing data. Glaucoma was mostly common in 50-64 years old (37.66%), male (50.65%), most patients lived in Surabaya (53.68%), the most common type was Primary Open-Angle Glaucoma (32.90%), the most medical therapy given in the first visit in 2019 was single medical therapy (67.97%), the most single drug therapy was latanoprost (49.68%), the most drugs combination was timolol maleat with acetazolamide (35.14%), the most commonly drugs class were prostaglandin analogues (48.48%), most of the visual acuity values were 6/6 - 6/18 (1,00 – 0,33) (37.88%), most intraocular pressure was in the 11-21 mmHg (62.55%). The most common type of glaucoma was primary open angle glaucoma with the most therapy given was prostaglandin analogue.


Glaucoma human & medicine single drug therapy combination drugs therapy prostaglandin analogue latanoprost health risk

Article Details

How to Cite
Praba, V. M., Primitasari, Y., Qorib, M. F., & Loebis, R. (2021). Selection of Medical Therapy in Glaucoma Patients in the Outpatient Eye Clinic Soetomo General Academic Hospital Surabaya. Folia Medica Indonesiana, 57(4), 324–333.


  1. Ariesti A, Herriadi D (2018). Profile of glaucoma at the Dr. M. Djamil hospital Padang, West Sumatera. Jurnal Kesehatan Andalas 7, 34-37.
  2. Baskaran M, Foo R, Cheng C, et al 2015). The prevalence and types of glaucoma in an urban chinese population. JAMA Ophthalmology 133, 874-880.
  3. Bowling B, Kanski JJ (2016). Kanski's clinical ophthalmology: A systematic approach 8th ed. Elsevier, Edinburg.
  4. Conlon R, Saheb H, Ahmed I (2017). Glaucoma treatment trends: A review. Canadian Journal of Ophthalmology 52, 114-124.
  5. Dienda M, Ibrahim I, Ramdja M (2013). Karakteristik penderita glaukoma di Klinik Mata Rumah Sakit Muhammadiyah Palembang tahun 2011. Syifa’ MEDIKA 4, 36-47.
  6. DiPiro JT, Talbert R, Yee GC, et al (2008). Pharmacotherapy: A pathophysiologic approach, 7th ed, McGraw-Hill Education, New York.
  7. Dizayang F, Bambang H, Purwoko M (2019). Karakteristik penderita glaukoma di Rumah Sakit Muhammadiyah Palembang periode Januari 2017-April 2018. Jurnal Ilmiah Kesehatan (Journal of Health Sciences) 13, 66-73.
  8. Fadly M (2020). Kualitas hidup pada penderita glaukoma berdasarkan national eye institute visual function questionnaire (NEI-VFQ). Universitas Sumatra Utara, Medan.
  9. Garway-Heath D, Crabb D, Bunce C, et al (2015). Latanoprost for open-angle glaucoma (UKGTS): A randomised, multicentre, placebo-controlled trial. The Lancet 385, 1295-1304.
  10. Hashemi H, Mohammadi M, Zandvakil N, et al (2019). Prevalence and risk factors of glaucoma in an adult population from Shahroud, Iran. Journal of Current Ophthalmology 31, 366-372.
  11. Hazhar SV (2017). Profil penderita glaukoma di Departemen/SMF Ilmu Kesehatan Mata RSUD Dr. Soetomo Surabaya 2014-2015. Universitas Airlangga, Surabaya.
  12. Helayel HB, AlOqab A, Al Subaie M, et al (2021). Profile of glaucoma in the Eastern region of Saudi Arabia: A retrospective study. Saudi Journal of Medicine & Medical Sciences 9, 167-174.
  13. Ismandari F, & Helda (2011). Kebutaan pada pasien glaukoma primer. Jurnal Kesehatan Masyarakat Nasional 5, 185-192.
  14. Japan Glaucoma Society (2006). Guidelines for glucoma. Available from Accessed March 28, 2020.
  15. Kyari F, Entekume G, Rabiu M, et al (2015). A population-based survey of the prevalence and types of glaucoma in Nigeria: Results from the Nigeria National Blindness and Visual Impairment Survey. BMC Ophthalmology 15, 1-15.
  16. Kyei S, Owusu-Afriyie B, Tagoh S, et al (2020). Clinical and sociodemographic characteristics of glaucoma patients at a tertiary referral facility in Zimbabwe. Malawi Medical Journal 33, 15-20.
  17. Li S, Chen R, Li Y, et al (2014). Meta-Analysis of randomized controlled trials comparing latanoprost with timolol in the treatment of Asian populations with chronic angle-closure glaucoma. PLoS ONE 9, 1-10.
  18. Liu B, McNally S, Kilpatrick J, et al (2018). Aging and ocular tissue stiffness in glaucoma. Survey of Ophthalmology 63, 56-74.
  19. Ministry of Health, Republic of Indonesia (2007). Riset kesehatan dasar tahun 2007. Badan Penelitian dan Pengembangan Kesehatan Kementrian Kesehatan RI, Jakarta.
  20. Ministry of Health, Republic of Indonesia (2013). Keputusan Menteri Kesehatan Republik Indonesia Nomor 328/Menkes/SK/VIII/2013 tentang Formularium Nasional. Departemen Kesehatan Republik Indonesia, Jakarta.
  21. Ministry of Health, Republic of Indonesia (2014). Peraturan Menteri Kesehatan Republik Indonesia Nomor 5 Tahun 2014 tentang panduan praktik klinis bagi dokter di fasilitas pelayanan kesehatan primer. Departemen Kesehatan Republik Indonesia, Jakarta.
  22. Mittal S, Mittal D (2021). Long-term glaucoma therapy trend in India. Scholars Journal of Applied Medical Sciences 9, 33-37.
  23. Mokhles P, van Gorcom L, Schouten J, et al (2020). Contributing ocular comorbidity to end-of-life visual acuity in medically treated glaucoma patients, ocular hypertension and glaucoma suspect patients. Eye 35, 883-891.
  24. Mustofa A, Ulfa N, Suryandari M (2016). Profil peresepan penyakit mata glaukoma pada pasien BPJS rawat jalan di RS Mata Masyarakat Jawa Timur periode Januari - Desember 2015. Journal of Pharmacy and Science 1, 27-33.
  25. Perry C, McGavin J, Culy C, et al (2003). Latanoprost: An update of its use in glaucoma and ocular hypertension. Drugs & Aging 20, 597-630.
  26. Pratista MB (2018). Efektivitas terapi medikamentosa, operasi, dan kombinasi terhadap penurunan tekanan intraokular penderita glaukoma di Instalasi Rawat Jalan Mata RSUD Dr. Soetomo Surabaya periode Januari–Desember 2017. Universitas Airlangga, Surabaya.
  27. Prum B, Rosenberg L, Gedde S, et al (2016). Primary open-angle glaucoma preferred practice pattern guidelines. Ophthalmology 123, P41-P111.
  28. Pusvitasari LW, Triningrat AAMP (2018). Profil pasien glaukoma di Poliklinik Mata Rumah Sakit Indera Provinsi Bali Periode Januari 2014-Juni 2015. E-Jurnal Medika Udayana 7, 189-193.
  29. Riordan-Eva P, Whitcher JP (2007). Vaughan and asbury’s general ophthalmology, 17th ed. The Mc Graw Hill, New York.
  30. Sakamoto M, Kitamura K, Kashiwagi K (2017). Changes in glaucoma medication during the past eight years and future directions in Japan based on an insurance medical claim database. Journal of Ophthalmology 2017, 1-6.
  31. Schehlein EM, Novack GD, Robin AL (2017). New classes of glaucoma medications. Current Opinion in Ophthalmology 28, 161-168.
  32. Schwartz G, Patel A, Naik R, et al (2021). Characteristics and treatment patterns of newly diagnosed open-angle glaucoma patients in the United States. Ophthalmology Glaucoma 4, 117-125.
  33. Shirai C, Matsuoka N, Nakazawa T (2021). Comparison of adherence between fixed and unfixed topical combination glaucoma therapies using Japanese healthcare/pharmacy claims database: A retrospective non-interventional cohort study. BMC Ophthalmol 21, 1-12.
  34. Stamper RL, Lieberman MF, Drake MV (2009). Diagnosis and therapy of the glaucomas, 8th ed, Mosby Elsevier, China.
  35. Tham Y, Li X, Wong T, et al (2014). Global prevalence of glaucoma and projections of glaucoma burden through 2040. Ophthalmology 121, 2081-2090.
  36. Yu L, Ding K, Luo L, et al (2020). Prescribing trends of glaucoma drugs in six major cities of China from 2013 to 2017. PLOS ONE 15, 1-10.